US Bancorp
TPST icon

US Bancorp’s Tempest Therapeutics TPST Stock Holding History

US Bancorp’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Hold
0
– – – 3635
2016
Q4 		– Hold
0
– – – 3638
2015
Q4 		– Sell
-1
Closed -$15K – 3699
2015
Q3 		$15K Buy
+1
New +$67.3K ﹤0.01% 2965

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

US Bancorp's TPST Position: Q1 2017 in Review

US Bancorp held its Tempest Therapeutics (TPST) position steady in Q1 2017 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3635.

US Bancorp first reported a position in TPST in Q3 2015 and has held it in 1 quarter since. The position peaked at $15K in Q3 2015. 63 funds tracked by Wall St. Rank hold TPST as of Q1 2017.

  • US Bancorp held 0 shares of Tempest Therapeutics worth $0 as of Q1 2017.
  • US Bancorp left its Tempest Therapeutics share count unchanged in Q1 2017.
  • Tempest Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2017, its #3635 holding.
  • US Bancorp first reported a position in Tempest Therapeutics in Q3 2015 and has held it in 1 quarter since.
  • US Bancorp's Tempest Therapeutics position peaked at $15K in Q3 2015.
  • 63 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2017.

Based on US Bancorp's 13F filing for Q1 2017, filed 3 May 2017.